Claims

1. An aqueous composition having a pH of from pH 7.0 to pH 8.5 comprising:
arginine at a concentration of from 50 mM to 150 mM;
Tris buffer, sodium chloride, sucrose, and sorbitol;
which composition is substantially free or is free of glutamic acid.

2. The composition according to claim 1, which composition is free of an added amino acid except for arginine.

3. The composition according to claim 1 or 2, which composition is substantially free or is free of a chelating agent.

4. The composition according to anyone of claims 1 to 3, comprising arginine at a concentration of from 75 mM to 125 mM, preferably 80 mM to 120 mM, more preferably 90 mM to 110 mM, even more preferably 95 mM to 105 mM, most preferably 100 mM.

5. The composition according to anyone of claims 1 to 4, comprising 10 mM Tris buffer.

6. The composition according to anyone of claims 1 to 5, comprising 140 mM sodium chloride.

7. The composition according to anyone of claims 1 to 6, comprising 10% (w/v) sucrose.

8. The composition according to anyone of claims 1 to 7, comprising 2% (w/v) sorbitol.

9. The composition according to anyone of claims 1 to 8, further comprising a poxvirus, preferably an orthopoxvirus, more preferably a vaccinia virus, even more preferably a modified vaccinia virus Ankara (MVA), most preferably MVA-BN®.

10. The composition according to claim 9, wherein the poxvirus is a recombinant poxvirus, most preferably a recombinant MVA, encoding at least one respiratory syncytial virus (RSV) protein or a part thereof.

11. A composition according to claim 9 or 10 for use as a medicament or a vaccine.

12. Use of a composition according to anyone of claims 1 to 8 for storing a poxvirus, preferably an orthopoxvirus, more preferably a vaccinia virus, even more preferably a modified vaccinia virus Ankara (MVA), most preferably MVA-BN®.

13. The use according to claim 12, wherein the poxvirus is a recombinant poxvirus, most preferably a recombinant MVA, encoding at least one respiratory syncytial virus (RSV) protein or a part thereof.

14. The use according to claim 12 or 13 for storing the poxvirus for at least 2 years at -50 degrees Celsius or -20 degrees Celsius.

15. The use according to claim 12 or 13 for storing the poxvirus for at least 6 months at +5 degrees Celsius, +20 degrees Celsius or +25 degrees Celsius.

16. A method of preparing a composition according to claim 9 or 10, the method comprising the steps of:

(i) providing a preparation comprising a poxvirus, preferably an ortho poxvirus, more preferably a vaccinia virus, even more preferably a modified vaccinia virus Ankara (MVA), most preferably MVA-BN®, in a pharmaceutically acceptable buffer, and

(ii) combining the poxvirus preparation of step (i) with the composition according to anyone of claims 1 to 8.

17. The method according to claim 16, wherein the poxvirus is a recombinant poxvirus, most preferably a recombinant MVA encoding at least one respiratory syncytial virus (RSV) protein or a part thereof.